Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma
Source: OncLive, September 2021
Filip Janku, MD, PhD, discusses the results form a phase 1 study (NCT02571036) of ripretinib (Qinlock), a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.
The data that came out of this study demonstrated a higher efficacy than what has previously been reported, according to Janku.
